Fifth Third Bancorp
KYMR icon

Fifth Third Bancorp’s Kymera Therapeutics KYMR Stock Holding History

Fifth Third Bancorp’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.53M Buy
65,659
+14,421
+28% +$1.24M 0.01% 584
2026
Q1 		$4.27M Buy
+51,238
New +$4.06M 0.01% 826

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Fifth Third Bancorp's KYMR Position: Q2 2026 in Review

Fifth Third Bancorp increased its Kymera Therapeutics (KYMR) stake by 28% in Q2 2026, buying an estimated $1.24M and bringing the position to 65,659 shares worth $7.53M. The position accounts for 0.01% of the portfolio, ranked #584.

Fifth Third Bancorp first reported a position in KYMR in Q1 2026 and has held it in 2 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Fifth Third Bancorp held 65,659 shares of Kymera Therapeutics worth $7.53M as of Q2 2026.
  • Fifth Third Bancorp bought 14,421 Kymera Therapeutics shares in Q2 2026, an estimated $1.24M.
  • Kymera Therapeutics made up 0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #584 holding.
  • Fifth Third Bancorp first reported a position in Kymera Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.